Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Aug 03, 2022 10:15am
102 Views
Post# 34867893

RE:RE:RE:RE:RE:RE:RE:Fireside Chat on August 10

RE:RE:RE:RE:RE:RE:RE:Fireside Chat on August 10

I don't think their original timeline was bad. It may have been the most optimistic scenario so we could have added a few months just for normal business. I think it's likely something intervened to throw things further off. It makes sense to me you don't update by saying "we've hit a snag, we'll get back to you". You work through the issue until you have clarity on the path forward. That's where the "we'll recruit 6 more at 300" comes in. I just read through each quarterly announcement starting Oct 21 and with hindsight they tell a story of them dealing with the repercussions of safety issues that arose from the 420 dose. It follows the usual pattern in biotech of always wanting to emphasize the positive and lacking detail but I'm reading between the lines that was the issue.

It's all very frustrating but it also all seems pretty normal for biotech.


 


Bucknelly21 wrote:

i dont think hes stupid but he aure could have corrected the timelines

 

palinc2000 wrote:

 

Yes he sure did!!So you also think that he is stupid for not meeting the November time line...

 

 

Bucknelly21 wrote: Paul dis say ph1a would be complete in November of last year... 


 

 





<< Previous
Bullboard Posts
Next >>